These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 12647196

  • 1. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH.
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [Abstract] [Full Text] [Related]

  • 2. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA.
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [Abstract] [Full Text] [Related]

  • 4. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A, Lau H, Magar R, Wang L, Devercelli G.
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
    Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI.
    Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group.
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [Abstract] [Full Text] [Related]

  • 12. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany.
    Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH, Munich RSV Study Group.
    Eur J Pediatr; 2003 Apr; 162(4):230-6. PubMed ID: 12647195
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD.
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [Abstract] [Full Text] [Related]

  • 14. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY, Mutlu B, Kavurt S, Baş AY, Demirel N, Akyol M, Erdeve O, Dilmen U.
    Turk J Pediatr; 2012 Jan; 54(4):344-51. PubMed ID: 23692714
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
    Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA.
    Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of palivizumab in New Zealand.
    Vogel AM, McKinlay MJ, Ashton T, Lennon DR, Harding JE, Pinnock R, Graham D, Grimwood K, Pattemore PK, Schousboe M.
    J Paediatr Child Health; 2002 Aug; 38(4):352-7. PubMed ID: 12173995
    [Abstract] [Full Text] [Related]

  • 18. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC.
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [Abstract] [Full Text] [Related]

  • 19. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA, Cosgrove JF, MacMahon P.
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [Abstract] [Full Text] [Related]

  • 20. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R, Dooley L, Bruden D, Raelson S, Butler JC.
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.